Update on Alzheimer’s Disease
With the disproportionate growth of the elderly population, Alzheimer’s disease (AD), as the most common cause of dementia, has become a major public health and socio-economic problem of our time. Updated consensus criteria for clinical diagnosis and new biomarkers have increased the diagnostic accu...
Main Author: | |
---|---|
Format: | Article |
Language: | English |
Published: |
European Medical Journal
2015-08-01
|
Series: | European Medical Journal Neurology |
Subjects: | |
Online Access: | http://emjreviews.com/wp-content/uploads/Update-on-Alzheimers-Disease.pdf |
id |
doaj-2551a32f8ac34ac5927694f702214732 |
---|---|
record_format |
Article |
spelling |
doaj-2551a32f8ac34ac5927694f7022147322020-11-25T00:56:38ZengEuropean Medical JournalEuropean Medical Journal Neurology2054-45292015-08-01318290Update on Alzheimer’s DiseaseKurt A. Jellinger0Institute of Clinical Neurobiology, Vienna, AustriaWith the disproportionate growth of the elderly population, Alzheimer’s disease (AD), as the most common cause of dementia, has become a major public health and socio-economic problem of our time. Updated consensus criteria for clinical diagnosis and new biomarkers have increased the diagnostic accuracy to over 90%, with a sensitivity versus other dementias of around 85% and a specificity of up to 78%, although a definite diagnosis depends on neuropathological examination. However, due to overlap between dementing disorders and frequent concurrence of multiple pathologies in the aged brain, both clinical and post-mortem studies entail biases that affect their validity. Harmonised interdisciplinary approaches are required to increase the accuracy and reproducibility of AD diagnosis as a basis for neuroprotection and efficient treatment. Preventative measures can minimise risk factors and confounding diseases, whereas anti-dementive treatment with drugs and non-pharmacological interventions can currently only delay the progression of the clinical course without causal effects. Better early diagnosis, active immunotherapies, and disease-modifying measures are the most important challenges for modern neurosciences.http://emjreviews.com/wp-content/uploads/Update-on-Alzheimers-Disease.pdfAlzheimer’s disease (AD)BiomarkersdementianeuropathologyTreatment |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Kurt A. Jellinger |
spellingShingle |
Kurt A. Jellinger Update on Alzheimer’s Disease European Medical Journal Neurology Alzheimer’s disease (AD) Biomarkers dementia neuropathology Treatment |
author_facet |
Kurt A. Jellinger |
author_sort |
Kurt A. Jellinger |
title |
Update on Alzheimer’s Disease |
title_short |
Update on Alzheimer’s Disease |
title_full |
Update on Alzheimer’s Disease |
title_fullStr |
Update on Alzheimer’s Disease |
title_full_unstemmed |
Update on Alzheimer’s Disease |
title_sort |
update on alzheimer’s disease |
publisher |
European Medical Journal |
series |
European Medical Journal Neurology |
issn |
2054-4529 |
publishDate |
2015-08-01 |
description |
With the disproportionate growth of the elderly population, Alzheimer’s disease (AD), as the most common cause of dementia, has become a major public health and socio-economic problem of our time. Updated consensus criteria for clinical diagnosis and new biomarkers have increased the diagnostic accuracy to over 90%, with a sensitivity versus other dementias of around 85% and a specificity of up to 78%, although a definite diagnosis depends on neuropathological examination. However, due to overlap between dementing disorders and frequent concurrence of multiple pathologies in the aged brain, both clinical and post-mortem studies entail biases that affect their validity. Harmonised interdisciplinary approaches are required to increase the accuracy and reproducibility of AD diagnosis as a basis for neuroprotection and efficient treatment. Preventative measures can minimise risk factors and confounding diseases, whereas anti-dementive treatment with drugs and non-pharmacological interventions can currently only delay the progression of the clinical course without causal effects. Better early diagnosis, active immunotherapies, and disease-modifying measures are the most important challenges for modern neurosciences. |
topic |
Alzheimer’s disease (AD) Biomarkers dementia neuropathology Treatment |
url |
http://emjreviews.com/wp-content/uploads/Update-on-Alzheimers-Disease.pdf |
work_keys_str_mv |
AT kurtajellinger updateonalzheimersdisease |
_version_ |
1725226229780447232 |